ECOR electroCore

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.

Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions.

Conference Call & Webcast Details

Date: Wednesday, March 12, 2025

Time: 5:30 PM EDT

Registration:  to receive login credentials and dial-in details.

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets.

For more information, visit .

Contact:

ECOR Investor Relations

(973) 302-9253



EN
06/03/2025

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce Fourth Quarter and Full Year Ended December 31...

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025 ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Deta...

March 6, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Participate at Upcoming Investor Conferences

electroCore to Participate at Upcoming Investor Conferences Management to Attend the 37th Annual Roth Conference and the LSI USA '25 ROCKAWAY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in two upcoming investor conferences. Management will attend and engage with investors at: The 37th Annual Roth Conference March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. Joshua Lev, Chief Financial Officer, will host one-on-...

March 5, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Di...

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomedical, an FDA cleared non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities. “At Spark Biomedi...

February 27, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore’s Truvaga™ Now Available on Amazon®

electroCore’s Truvaga™ Now Available on Amazon® Leading Direct to Consumer Vagus Nerve Stimulator Available for Purchase on World’s Largest Retail Platform ROCKAWAY, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its flagship wellness product, , is now available for purchase on Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relie...

February 19, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio electroCore Granted Two New U.S. Patents ROCKAWAY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received two patent issue notifications from the United States Patent and Trademark Office (USPTO). US Patent No. 12,208,263 entitled “Devices and Methods for Vagal Nerve Stimulation” was issued on January 28, 2025 and generally relates to methods for modulating the vagus nerve by positioning an electrode in contact with ...

February 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch